News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
680,098 Results
Type
Article (38836)
Company Profile (249)
Press Release (641013)
Section
Business (203611)
Career Advice (1979)
Deals (35351)
Drug Delivery (79)
Drug Development (80689)
Employer Resources (167)
FDA (16041)
Job Trends (14782)
News (343923)
Policy (32418)
Tag
Academia (2529)
Africa (712)
Alliances (48990)
Alzheimer's disease (1158)
Approvals (15973)
Arizona (176)
Artificial intelligence (80)
Asia (36858)
Australia (5999)
Bankruptcy (351)
Best Places to Work (11339)
Biosimilars (65)
Biotechnology (180)
Breast cancer (69)
C2C Services and Suppliers (78790)
California (2069)
Canada (995)
Cancer (586)
Career advice (1649)
Cell therapy (143)
China (163)
Clinical research (63428)
Collaboration (184)
Colorado (86)
Compensation (101)
Connecticut (88)
COVID-19 (2499)
Cystic fibrosis (78)
Data (468)
Diabetes (94)
Diagnostics (6001)
Drug pricing (71)
Earnings (83691)
Employer resources (142)
Europe (78805)
Events (108026)
Executive appointments (178)
FDA (16332)
Florida (299)
Funding (178)
Gene therapy (100)
GLP-1 (524)
Government (4302)
Healthcare (18617)
Hotbed/Location (480948)
Illinois (270)
Indiana (152)
Infectious disease (2536)
Inflammatory bowel disease (93)
Interviews (306)
IPO (16212)
Job creations (3618)
Job search strategy (1413)
Kansas (94)
Layoffs (397)
Legal (7833)
Lung cancer (120)
Manufacturing (106)
Maryland (426)
Massachusetts (1689)
Medical device (13070)
Medtech (13075)
Mergers & acquisitions (19039)
Metabolic disorders (280)
Michigan (130)
Minnesota (222)
Neuroscience (1338)
New Jersey (640)
New York (649)
NextGen Class of 2024 (6482)
Non-profit (4457)
North Carolina (604)
Northern California (904)
Obesity (170)
Ohio (113)
Opinion (172)
Patents (79)
Pennsylvania (624)
People (55920)
Phase I (19646)
Phase II (27921)
Phase III (20882)
Pipeline (135)
Postmarket research (2549)
Preclinical (8334)
Press Release (64)
Radiopharmaceuticals (230)
Rare diseases (151)
Real estate (5884)
Regulatory (21283)
Research institute (2305)
Resumes & cover letters (347)
South America (1089)
Southern California (839)
Startups (3560)
Texas (270)
United States (9272)
Vaccines (491)
Washington State (261)
Weight loss (137)
Date
Today (161)
Last 7 days (642)
Last 30 days (2742)
Last 365 days (36929)
2024 (27200)
2023 (40075)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46542)
2018 (35019)
2017 (32111)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27328)
680,098 Results for "chemdiv inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
ChemDiv to Participate in the EF Hutton Annual Global Conference, May 15, 2024
ChemDiv, Inc, announced that Bill Farley, CEO, will participate in the EF Hutton Annual Global Conference.
May 13, 2024
·
1 min read
Drug Development
ChemDiv Marks a Milestone as Orionis Biosciences’ Novel Immunotherapy Enters Phase I Clinical Trials
ChemDiv Inc, a leading provider of drug discovery platforms and development solutions, celebrates a significant milestone in collaboration with Orionis Biosciences: the commencement of Phase I clinical trials for ORB-011, a cutting-edge attenuated, cis-targeted interferon immunotherapy compound.
January 3, 2024
·
1 min read
Drug Development
ChemDiv Helps Advance Viriom’s Influenza Treatment to Successful Phase I Clinical Trials Completion
ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces successful completion of Phase I clinical trials for AV5124, an innovative influenza virus replication inhibitor being developed by Viriom Inc. (Viriom).
December 19, 2023
·
2 min read
Business
ChemDiv Establishes a Cutting-edge Biology Facility in Portugal
ChemDiv Inc, a global leader in drug discovery and drug development solutions, shares the progress in the development of its cutting-edge biology facility at Biocant Park, Cantanhede, Portugal.
August 16, 2023
·
2 min read
Biotech Beach
ChemDiv Forges Strategic Partnership with The University of Texas Medical Branch (UTMB) to Expand Its High-throughput Screening Research Capabilities
ChemDiv announces a strategic collaboration with the University of Texas Medical Branch to facilitate the expansion of its inventory and advance the institution’s High-throughput Screening research programs.
December 28, 2023
·
1 min read
Biotech Beach
ChemDiv Presented Non-Clinical Summary Data for The Best-in-Class Selective FLT3 Clinical Candidate at the 65th ASH Annual Meeting and Exposition with Its Partners and Sponsors
ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces the presentation of non-clinical summary data for the best-in-class selective FLT3 clinical candidate at the 65th ASH Annual Meeting and Exposition in San Diego, CA.
December 12, 2023
·
2 min read
Business
ChemDiv Welcomes Peter Dmitriev and David Stark to Business Development Team, Announces Headquarters Expansion
ChemDiv is excited to announce the expansion of its Business Development Team with the addition of two seasoned professionals, Peter Dmitriev as Business Development Manager and David Stark as Senior Regional Director of Business Development.
October 25, 2023
·
2 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
1 of 68,010
Next